CompletedPhase 4

Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery

China100 participantsStarted 2023-09-01

Plain-language summary

The goal of this clinical trial is to compare the weight loss and metabolic benefit in patients remaining obesity at 6 months after metabolic surgery. The main questions it aims to answer are: \[primary hypothesis 1\] Whether liraglutide benefits weight loss when it is initiated early after metabolic surgery. \[primary hypothesis 2\] Whether weight loss and metabolic benefits are greater when linaglutide is initiated in patients who are obese at 6 months after metabolic surgery

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients 6 months after metabolic surgery; * 18 years ≤ age ≤ 65 years; * Body Mass Index (BMI) ≥ 28 kg/m\^2 Exclusion Criteria: * allergy to liraglutide, severe hepatic or renal impairment (eGFR \<60 mL/min/1.73 m² or ALT/AST ≥3× ULN) * history of medullary thyroid carcinoma, MEN-2 or other malignancies * pancreatitis or severe gastrointestinal disease, pregnancy or lactation * use of anti-obesity drugs or other interventional trials within 3 months or major uncontrolled illness * Patients were discontinued if withdrawn, intolerant, lost to follow-up, or developed severe adverse events.

What they're measuring

Change in %TWL from baseline to endpoint across patient groups

Timeframe: 48 weeks from enrollment

Trial details

NCT IDNCT07374445

SponsorThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-01

View on ClinicalTrials.gov More Obesity trials